chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling drunk, Paraesthesia oral
Clinical narrative: Tongue felt tingly and felt drunk; Tongue felt tingly and felt drunk; Blood sugar was 40 points below normal; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 24Apr2021 at 12:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes. The patient previously had penicillin for unknown indication on unknown date and experienced penicillin allergy. Concomitant medications taken within two weeks of vaccination were not reported. The patient previously took valproate semisodium (DEPAKOTE) for unknown indication on unknown date and experienced drug allergy. The patient previously also took morphine (MANUFACTURER UNKNOWN) for unknown indication on unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021 at 13:00, the patients tongue felt tingly and felt drunk. Also, blood sugar was 40 points below normal. Therapeutic measures were taken as a result of tongue felt tingly and felt drunk, blood sugar was 40 points below normal and included Ambulance check. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events tongue felt tingly and felt drunk, blood sugar was 40 points below normal was resolved on 24Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal discomfort, Headache
Clinical narrative: Started to get Headaches on one side of head.; Upset Stomach for the past week and a half.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on an unknown date in Apr2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 12:00, the patient experienced headaches on one side of head and upset stomach for the past week and a half. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headaches on one side of head and upset stomach for the past week and a half was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pain, Vomiting
Clinical narrative: Vomiting; Body aches; Chills; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 23Apr2021 at 08:30 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy. The patient previously took bupropion hydrochloride (WELLBUTRIN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date at 08:30 as a single dose for COVID-19 immunisation. On 24Apr2021 at 02:00, the patient experienced vomiting, body aches and chills. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events vomiting, body aches and chills was resolving at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Headache; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 18:15 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021, the patient experienced headache. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event headache was resolving at the time of tis report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Lymphadenopathy, Malaise
Clinical narrative: Body aches; Headache; Chills; Tiredness; Swollen lymph nodes; Overall unwell feeling; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the right arm on 19Apr2021 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) taken for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the right arm on 29Mar2021 (at the age of 60-year-old) as a single dose for COVID-19immunisation. On 19Apr2021 at 21:00, the patient experienced headache, body aches, chills, tiredness, swollen lymph nodes and overall unwell feeling. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headache, body aches, chills, tiredness, swollen lymph nodes and overall unwell feeling were resolving at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Body aches; Headache; Chills; Tiredness; Swollen lymph nodes; Overall unwell feeling; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the right arm on 19Apr2021 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) taken for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the right arm on 29Mar2021 (at the age of 60-year-old) as a single dose for COVID-19immunisation. On 19Apr2021 at 21:00, the patient experienced headache, body aches, chills, tiredness, swollen lymph nodes and overall unwell feeling. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headache, body aches, chills, tiredness, swollen lymph nodes and overall unwell feeling were resolving at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Lymphadenopathy
Clinical narrative: Swollen arm pit lymph node under right arm. (About  the size of a small egg.); Swollen arm pit lymph node under right arm. (About the size of a small egg.) It also hurts.; This is a spontaneous report from a non-contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 18Apr2021 at 12:30 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient  was diagnosed with COVID-19. The patient had no known allergies to medications, food or other products and did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisdexamfetamine mesilate (VYVANSE) from an unknown date for unknown indication and unknown if ongoing. On 19Apr2021, the patient experienced swollen arm pit lymph node under right arm (about the size of a small egg) and it hurted. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swollen arm pit lymph node under right arm (about the size of a small egg) that also hurted was not recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Dry mouth, Food aversion, Inappropriate schedule of product administration, Parosmia, Taste disorder
Clinical narrative: Altered sense of smell; Distinctly foul taste in mouth. Altered taste (aversion) to specific foods. Example: eggs, peanut butter , pretzels, beef; Excessively dry mouth.; Altered taste (aversion) to specific foods. Example: eggs, peanut butter, pretzels, beef; Inappropriate schedule of vaccine administered; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 12Mar2021 at 12:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism, anxiety and COVID-19. The patient had no known allergies to medications, food, or other products. The patient received concomitant medication (unspecified) within two weeks of vaccination on unknown date for unknown indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 26Feb2021 at 12:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On13Mar2021 at 12:00 the patient experienced altered sense of smell. She also experienced a distinctly foul taste in mouth. The patient had excessively dry mouth. She experienced altered taste (aversion) to specific foods. Example: eggs, peanut butter , pretzels, beef. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events altered sense of smell; a distinctly foul taste in mouth; excessively dry mouth; altered taste (aversion) to specific foods, example: eggs, peanut butter , pretzels, beef was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus.; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 27-year-old) as a single dose for COVID-19immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date the patient experienced tinnitus. The patient reported that it had ruined his life. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tinnitus was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Discomfort, Joint swelling, Nausea, Pain, Paraesthesia
Clinical narrative: Both legs became tingling/ tingling radiated frombehind knees into calves and upto buttock; Nausea feeling; Uncomfortable to sit for any period of time; Behind knees were slightly swollen; Occasional sharp pain; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 18Mar2021 at 09:00 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included controlled anemia, exercised induced asthma and sensitive to sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included iron supplement (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. On 20Mar2021 at 08:00 (also reported as 2 days following shot), the patient's both legs became tingling. The patient had nausea feeling and was uncomfortable to sit for any period of time. Behind knees were slightly swollen and the tingling radiated from behind knees into calves and up to buttock. The patient had occasional sharp pain which was only a couple of days. It had been over 6 weeks and still the patient was not back to normal. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19.  On an unknown date, the patient underwent COVID test via nasal swab and the result was negative. Therapeutic measures were taken as a result of events and included unspecified treatment and urgent care, family doctor, emergency room visit and many tests were conducted. The clinical outcome of the events both legs became tingling/tingling radiated from behind knees into calves and up to buttock, nausea feeling, uncomfortable to sit for any period of time, behind knees were slightly swollen and occasional sharp pain were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Both legs became tingling/ tingling radiated frombehind knees into calves and upto buttock; Nausea feeling; Uncomfortable to sit for any period of time; Behind knees were slightly swollen; Occasional sharp pain; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 18Mar2021 at 09:00 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included controlled anemia, exercised induced asthma and sensitive to sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included iron supplement (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. On 20Mar2021 at 08:00 (also reported as 2 days following shot), the patient's both legs became tingling. The patient had nausea feeling and was uncomfortable to sit for any period of time. Behind knees were slightly swollen and the tingling radiated from behind knees into calves and up to buttock. The patient had occasional sharp pain which was only a couple of days. It had been over 6 weeks and still the patient was not back to normal. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19.  On an unknown date, the patient underwent COVID test via nasal swab and the result was negative. Therapeutic measures were taken as a result of events and included unspecified treatment and urgent care, family doctor, emergency room visit and many tests were conducted. The clinical outcome of the events both legs became tingling/tingling radiated from behind knees into calves and up to buttock, nausea feeling, uncomfortable to sit for any period of time, behind knees were slightly swollen and occasional sharp pain were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: Adverse drug reaction, Irritable bowel syndrome
Clinical narrative: IBS flared up with all foods and environments; Physical side effects; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0172) via an unspecified route of administration on 23Apr2021 at 08:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included metal implant from vehicle accident in 2010 and episodes of irritable bowel syndrome (IBS) on and off for ten years. It was reported that the most extreme and painful episodes of IBS were directly after diagnosis. The patient had no known allergies. Prior to the vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included oxycodone (MANUFACTURER UNKNOWN) and unspecified nonsteroidal anti-inflammatory drugs (NSAIDs) (MANUFACTURER UNKNOWN), both were for unspecified indications from unknown dates and unknown if ongoing. On 23Apr2021 at 18:00, the patient's IBS flared up with all foods and environments. It was reported that most other physical side effects were gone but the IBS episodes were constant. On 25Apr2021, the patient would be purchasing dicycloamine products (MANUFACTURER UNKNOWN) to control symptoms and prepare for second dose. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of physical side effects was recovered on an unknown date in Apr2021 and outcome of the event IBS flared up with all foods and environments was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Lymphadenopathy left underarm; This is a spontaneous report from a contactable physician, the patient. A 44-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 22Apr2021 at 10:45 (at the age of 44-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW8727) via an unknown route of administration in the right arm on 01Apr2021 at 14:15 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. On 24Apr2021, the patient experienced lymphadenopathy left underarm. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the event and included treatment with ibuprofen (MANUFACTURER UNKNOWN) 400 mg. The clinical outcome of the event lymphadenopathy left underarm was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Fatigue, Headache, Nausea
Clinical narrative: Dizziness; Headache; Weakness; Nausea; Exhaustion; Pain and difficulty raising injection site arm; Pain and difficulty raising injection site arm; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 24Apr2021 at 10:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and allergies, hemiplegic migraines, penicillin allergy and allergy to certain opioids. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included salbutamol (ALBUTEROL) and acetylsalicylic acid/caffeine/paracetamol (EXCEDRIN), eye drops (unspecified) and birth control pill (unspecified); all for an unknown indication from an unknown date and unknown if ongoing. On 24Apr2021 at 10:30, the patient experienced dizziness, headache, weakness, nausea, exhaustion, and pain and difficulty raising injection site arm. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events dizziness, headache, weakness, nausea, exhaustion, and pain and difficulty raising injection site arm were not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pain in extremity
Clinical narrative: Dizziness; Headache; Weakness; Nausea; Exhaustion; Pain and difficulty raising injection site arm; Pain and difficulty raising injection site arm; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 24Apr2021 at 10:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and allergies, hemiplegic migraines, penicillin allergy and allergy to certain opioids. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included salbutamol (ALBUTEROL) and acetylsalicylic acid/caffeine/paracetamol (EXCEDRIN), eye drops (unspecified) and birth control pill (unspecified); all for an unknown indication from an unknown date and unknown if ongoing. On 24Apr2021 at 10:30, the patient experienced dizziness, headache, weakness, nausea, exhaustion, and pain and difficulty raising injection site arm. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events dizziness, headache, weakness, nausea, exhaustion, and pain and difficulty raising injection site arm were not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Oropharyngeal discomfort, Throat irritation
Clinical narrative: Slight irritation in the throat; Discomfort in the throat; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 10:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. The patient did not receive any medication within two weeks of vaccination.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021 at 07:00, since second day of vaccination, the patient experienced slight irritation and discomfort in the throat. The patient had no other side effects. The patient had doubt whether the events were expected with vaccine. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events slight irritation and discomfort in the throat was unknown at the time of report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Paraesthesia, Rhinorrhoea
Clinical narrative: Metallic taste in throat; Runny tingly nose nostril; Runny tingly nose nostril; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 25Apr2021 at 12:00 (at the age of 48-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on unknown date in 2021 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Apr2021 at 12:30, the patient experienced metallic taste in throat, runny tingly nose nostril. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event metallic taste in throat, runny nose and tingly nose nostril was unknown at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Heart rate, Heart rate irregular
Clinical narrative: Irregular heartbeat; This is a spontaneous report from a contactable consumer, the patient. A 76-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 08Mar2021 at 11:00 (at the age of 76-years-old) as a single dose for COVID-19 immunisation. Medical history included food allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the left arm on 15Feb2021 at 11:00 as a single dose for COVID-19 immunisation. On 10Mar2021 at 06:00, the patient experienced irregular heartbeat. No adverse symptoms with this. Felt fine, blood pressure (BP) and Pulse normal. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in Mar2021, the patient underwent blood pressure and the result was normal. On an unknown date in Mar2021, the patient underwent pulse rate and the result was normal. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event irregular heartbeat was recovered on an unknown date in Mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Lymph node swelling in both breasts; Lymph node tenderness and mild pain; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the right arm on 09Apr2021 at 12:45 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included estradiol (MANUFACTURER UNKNOWN), thyroid (ARMOUR THYROID) and progesterone (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates and unknown if ongoing. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 19Mar2021 at 11:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. On 15Apr2021, the patient experienced lymph node swelling in both breasts, tenderness and mild pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19.Therapeutic measures were not taken as a result of events. The clinical outcome of the events lymph node swelling in both breasts, lymph node tenderness and mild pain were recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Disease recurrence, Migraine, Migraine with aura, SARS-CoV-2 test
Clinical narrative: Mild migraine headache; Mild migraine headache; Weeks later it returned and been coming with much more strength and aura; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the left arm on 21Feb2021 at 08:00 (at the age of 74-year-old) as a single dose for COVID-19 immunisation. Medical history included migraine (years ago, the patient used to have migraines but haven't had them in many years), degenerative disc disease of the spine, nerve block, high blood pressure (BP), and cholesterol. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included losartan (MANUFACTURER UNKNOWN), topiramate (MANUFACTURER UNKNOWN), famotidine (MANUFACTURER UNKNOWN), and loratadine (MANUFACTURER UNKNOWN); all from unknown dates for unknown indications. The patient previously received the first dose (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9269) via an unspecified route of administration in the left arm on 31Jan2021 at 08:00 (at the age of 74-year-old) as a single dose for COVID-19 immunisation. On 21Feb2021 at 16:00, the afternoon of the second COVID shot, the patient experienced a mild migraine headache. It appeared only when standing and sitting but went away when the patient laid down. It happened the next day also and a few days later, it came back. On an unknown date in 2021, weeks later it had returned and had been coming with much more strength, aura and nausea. The patient reported that the COVID vaccine had triggered migraines again and the patient hoped that would go away. Each time it was getting worse. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department, or urgent care. Since the vaccination, the patient had been tested for COVID-19. On 08Apr2021, the patient underwent a nasal swab test and the result was negative. Therapeutic measures were not taken as a result of the events. The clinical outcome of events mild migraine headache and weeks later it returned and been coming with much more strength and aura was not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Poor quality sleep, Vaccination site pain
Clinical narrative: Headache; Tiredness; Pain around the area of the injection site; Poor sleep; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date in Apr2021 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had allergies to unspecified medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included vitamin D (MANUFACTURER UNKNOWN) and multivitamin supplements (MANUFACTURER UNKNOWN), taken for an unknown indication from an unknown date and unknown if ongoing. On an unknown date in Apr2021, the patient experienced headache, tiredness, pain around the area of the injection site, and poor sleep. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headache, tiredness, pain around the area of the injection site, and poor sleep were resolving at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Disease recurrence, Dizziness, Labyrinthitis, Nausea, Restlessness
Clinical narrative: Vertigo; Nausea; Restlessness; Occasional light headiness; Labyrinthitis/2nd vaccine may have triggered the acute symptoms return; Labyrinthitis/2nd vaccine may have triggered the acute symptoms return; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 31Mar2021 at 12:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies, penicillin allergy and labyrinthitis. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. Concomitant medication included levocetirizine dihydrochloride (XYZAL) taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 08Mar2021 at 15:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. On 01Apr2021 at 13:00, initially the patient experienced vertigo, nausea and restlessness that lasted 48 hours post the second shot. The patient had a sporadic repeat of these symptoms on three additional occasions that lasted 2 to 3 hours. The patient reported that he had just occasional light headiness at the time of the report. The patient was successfully treated for labyrinthitis in Sep2020 and was 100 percent symptom free until the second vaccine. The patient's doctor suspected that the second vaccine might had triggered the acute symptoms to return. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the event nausea and included treatment with nausea medication (unspecified). The clinical outcome of the events vertigo, nausea, restlessness, occasional light headiness and labyrinthitis/second vaccine may have triggered the acute symptoms return was resolving at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Vertigo; Nausea; Restlessness; Occasional light headiness; Labyrinthitis/2nd vaccine may have triggered the acute symptoms return; Labyrinthitis/2nd vaccine may have triggered the acute symptoms return; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 31Mar2021 at 12:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies, penicillin allergy and labyrinthitis. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. Concomitant medication included levocetirizine dihydrochloride (XYZAL) taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 08Mar2021 at 15:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. On 01Apr2021 at 13:00, initially the patient experienced vertigo, nausea and restlessness that lasted 48 hours post the second shot. The patient had a sporadic repeat of these symptoms on three additional occasions that lasted 2 to 3 hours. The patient reported that he had just occasional light headiness at the time of the report. The patient was successfully treated for labyrinthitis in Sep2020 and was 100 percent symptom free until the second vaccine. The patient's doctor suspected that the second vaccine might had triggered the acute symptoms to return. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the event nausea and included treatment with nausea medication (unspecified). The clinical outcome of the events vertigo, nausea, restlessness, occasional light headiness and labyrinthitis/second vaccine may have triggered the acute symptoms return was resolving at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Memory impairment, Pain in extremity, Vaccination site swelling
Clinical narrative: Clouded memory; Sore arm; Headache; Swelling around injection site; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 19Apr2021 at 13:45 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, high triglycerides, high blood pressure, and fatty liver. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included empagliflozin (JARDIANCE), metformin hydrochloride (METFORMIN ER), atorvastatin (MANUFACTURER UNKNOWN) and fenofibrate (MANUFACTURER UNKNOWN) all since unknown dates for unknown indications and unknown if ongoing. On 20Apr2021 at 00:00, the patient experienced sore arm, headache, swelling around the injection site, and clouded memory. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events sore arm, headache, swelling around injection site, and clouded memory was not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenopia, Dry eye, Eye pain, Hordeolum
Clinical narrative: by 3rd day had a sty in my left eye; Morning after shot, woke up with pain in my left eye when I blinked.; Both eyes felt heavy; Eyes dry like sandpaper; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Mar2021 at 09:00 (at the age of 68-years-old), as a single dose for COVID-19 immunisation. Medical history included blood pressure high and asthma. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included losartan potassium (LOSARTIN) and montelukast sodium (SINGULAIR); both for unspecified indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 18Mar2021, morning after shot, the patient woke up with pain in left eye when blinked. Both eyes felt heavy and eyes dry like sandpaper. By third day, on 20Mar2021, patient had sty in left eye. Took 2 weeks to heal. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events woke up with pain in left eye when blinked, both eyes felt heavy and eyes dry like sandpaper and sty in left eye was recovered on unknown date of Apr2021.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Pain
Clinical narrative: Body aches; Swollen lymph nodes under armpit in the arm that was injected; Swollen lymph nodes above clavicle in the arm that was injected; This is a spontaneous report from a non-contactable consumer, the patient. A 31-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the arm on 18Apr2021 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. The patients' medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date in Apr2021 the patient experienced body aches and swollen lymph nodes under armpit and above clavicle in the arm that was injected. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events body aches and swollen lymph nodes under armpit and above clavicle in the arm that was injected were unknown at the time of this report.   No follow-up attempts are possible. No further information is expected.